Daniel Faga - 20 Apr 2026 Form 4 Insider Report for First Tracks Biotherapeutics, Inc. (TRAX)

Reporting relationship: President, CEO, Director
Issuer ticker: TRAX
Reported as of: 20 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Apr 2026, 16:05:11 UTC
Prior SEC filing: 01 Apr 2026
Next SEC filing: 14 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Ajim Tamboli, Attorney-in-Fact

Key filing fact

Daniel Faga filed Form 4 for First Tracks Biotherapeutics, Inc. (TRAX) on 22 Apr 2026.

Key facts

This page summarizes Daniel Faga's Form 4 filing for First Tracks Biotherapeutics, Inc. (TRAX).
11 reported transactions and 11 derivative rows are listed below.
Accepted by SEC: 22 Apr 2026, 16:05.

Change

Previous filing in this sequence was filed on 01 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001673528 Primary reporting owner

Faga Daniel

Relationship: President, CEO, Director
Address: 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO
Signature: /s/ Ajim Tamboli, Attorney-in-Fact
Signature date: 22 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TRAX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 496,684
Date: 20 Apr 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TRAX transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
Shares: +11,000
Change %
Price: $0.000000^*
Shares after: 11,000
Date: 20 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,000
Exercise price: $8.33
Footnotes: F2, F3

TRAX transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
Shares: +2,321
Change %
Price: $0.000000^*
Shares after: 2,321
Date: 20 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,321
Exercise price: $8.33
Footnotes: F2, F3

TRAX transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
Shares: +9,200
Change %
Price: $0.000000^*
Shares after: 9,200
Date: 20 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,200
Exercise price: $8.14
Footnotes: F2, F3

TRAX transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
Shares: +194,900
Change %
Price: $0.000000^*
Shares after: 194,900
Date: 20 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 194,900
Exercise price: $6.22
Footnotes: F2, F4

TRAX transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
Shares: +379,620
Change %
Price: $0.000000^*
Shares after: 379,620
Date: 20 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 379,620
Exercise price: $5.67
Footnotes: F2, F5

TRAX transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
Shares: +305,500
Change %
Price: $0.000000^*
Shares after: 305,500
Date: 20 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 305,500
Exercise price: $3.97
Footnotes: F2, F6

TRAX transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
Shares: +133,400
Change %
Price: $0.000000^*
Shares after: 133,400
Date: 20 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 133,400
Exercise price: $11.75
Footnotes: F2, F7

TRAX transaction Derivative

Restricted Stock Unit

Award

Transaction value
Shares: +17,850
Change %
Price: $0.000000^*
Shares after: 17,850
Date: 20 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,850
Exercise price
Footnotes: F8, F9, F10

TRAX transaction Derivative

Restricted Stock Unit

Award

Transaction value
Shares: +69,355
Change %
Price: $0.000000^*
Shares after: 69,355
Date: 20 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 69,355
Exercise price
Footnotes: F8, F9, F11

TRAX transaction Derivative

Restricted Stock Unit

Award

Transaction value
Shares: +80,512
Change %
Price: $0.000000^*
Shares after: 80,512
Date: 20 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 80,512
Exercise price
Footnotes: F8, F9, F12

TRAX transaction Derivative

Restricted Stock Unit

Award

Transaction value
Shares: +98,600
Change %
Price: $0.000000^*
Shares after: 98,600
Date: 20 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 98,600
Exercise price
Footnotes: F8, F9, F13

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 13 footnotes

Footnote F1

Consists of shares of common stock received in connection with the spin-off of First Tracks Biotherapeutics, Inc. ("First Tracks") from AnaptysBio, Inc. ("AnaptysBio").

Footnote F2

Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement.

Footnote F3

The stock option is fully vested and exercisable.

Footnote F4

The stock option vests as to 25% of the total shares on January 6, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F5

The stock option vests as to 25% of the total shares on January 3, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F6

The stock option vests as to 25% of the total shares on January 7, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F7

The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F8

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

Footnote F9

Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding restricted stock unit ("RSU") with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSUs with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement.

Footnote F10

The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F11

The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F12

The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F13

The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.